SciSparc: NeuroThera Labs Announces Initiation of Phase IIb Clinical Trial at Hannover Medical School in Germany for Innovative Treatment of Tourette Syndrome
SciSparc’s subsidiary NeuroThera Labs has initiated a Phase IIb clinical trial for SCI-110, its proprietary cannabinoid-based treatment for Tourette Syndrome, at the Hannover Medical School in Germany. The randomized, double-blind, placebo-controlled study will enroll adults aged 18-65, with primary efficacy endpoints measured at weeks 12 and 26, and will also be conducted at Yale Child Study Center and Tel Aviv Sourasky Medical Center.
Key figures
- Drug Name
- SCI-110
- Phase Of Trial
- Phase IIb
- Patient age range
- 18-65
- Phase2a tic reduction
- 21%
- Primary endpoint weeks
- 12 and 26
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.